Literature DB >> 11251225

Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes.

A A Tulub1, V E Stefanov.   

Abstract

Despite numerous studies considering DNA as a primary target of cisplatin attack, this work is the first to show the pure effect of cisplatin on the process of tubulin assembly/disassembly in vitro. When platinated, tubulin does not assemble into microtubules (direct electron microscopic studies). In place of them, highly stable and inert circled rings arise. Such tubulin aggregates are unable to participate in the process of chromosome separation during the mitosis, thus blocking cell division in living cells, which is a direct evidence of cisplatin antitumor activity. Cisplatin attack on tubulin causing blockage of tubulin assembly occurs via a two-step binding to GTP in the GTP center of tubulin ((195)Pt, (31)P NMR studies). The calculated binding rates are close to those reported in cisplatin-DNA interactions. The mechanism of cisplatin attack on tubulin is proposed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251225     DOI: 10.1016/s0141-8130(00)00159-8

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  18 in total

1.  Irradiation of tubulin solution in vitro by electrons causes self-assembly of tubulin into microtubules in the absence of magnesium cations.

Authors:  V E Stefanov; A A Tulub
Journal:  Dokl Biol Sci       Date:  2003 Sep-Oct

2.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.

Authors:  Anil Belur Nagaraj; Olga Kovalenko; Rita Avelar; Peronne Joseph; Annalyn Brown; Arshia Surti; Sandra Mantilla; Analisa DiFeo
Journal:  Clin Cancer Res       Date:  2018-04-13       Impact factor: 12.531

4.  Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.

Authors:  Li Wang; Fang Yin; Yulei Du; Bei Chen; Shuhui Liang; Yongguo Zhang; Wenqi Du; Kaichun Wu; Jie Ding; Daiming Fan
Journal:  Tumour Biol       Date:  2010-05-04

Review 5.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

6.  Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo.

Authors:  Xiang Ling; David Westover; Felicia Cao; Shousong Cao; Xiang He; Hak-Ryul Kim; Yuesheng Zhang; Daniel Cf Chan; Fengzhi Li
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

7.  Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma.

Authors:  Han-Ping Hsu; Chien-Feng Li; Sung-Wei Lee; Wen-Ren Wu; Tzu-Ju Chen; Kwang-Yu Chang; Shih-Shin Liang; Chia-Jung Tsai; Yow-Ling Shiue
Journal:  Tumour Biol       Date:  2013-11-12

8.  Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells.

Authors:  Concepcion Conejero-Goldberg; Kirk Townsend; Peter Davies
Journal:  J Mol Neurosci       Date:  2008-02-16       Impact factor: 3.444

9.  Endocytic recycling compartments altered in cisplatin-resistant cancer cells.

Authors:  Xing-Jie Liang; Sushmita Mukherjee; Ding-Wu Shen; Frederick R Maxfield; Michael M Gottesman
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors.

Authors:  Jonathan G Mehtala; Sandra Torregrosa-Allen; Bennett D Elzey; Mansik Jeon; Chulhong Kim; Alexander Wei
Journal:  Nanomedicine (Lond)       Date:  2014-02-05       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.